Essentialis is a pharmaceutical company focused on the development of breakthrough medicines for the treatment of metabolic and cardiovascular diseases.
The company's portfolio of products is targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of metabolic and cardiovascular diseases.
The company is currently planning to advance it's lead product, DCCR (Diazoxide Choline Controlled-Release Tablet), into Phase 3 trials in patients with very high triglycerides (VHTG: TG > 500 mg/dL). Reaching the TG treatment goals is the most pressing unmet medical need in the treatment of VHTG patients. Nearly 75% of treated VHTG patients fail to reach the TG goal set by their physicians on a single TG-lowering agent. There is, therefore, a need for new TG-lowering therapies which are additive to currently approved VHTG drugs to increase the likelihood that treated VHTG patients reach TG goals. Essentialis's phase 3 clinical program is designed to evaluate DCCR as monotherapy and as add-on therapy to fenofibrate.